Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

146 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Profiling of drug-metabolizing enzymes/transporters in CD33+ acute myeloid leukemia patients treated with Gemtuzumab-Ozogamicin and Fludarabine, Cytarabine and Idarubicin.
Iacobucci I, Lonetti A, Candoni A, Sazzini M, Papayannidis C, Formica S, Ottaviani E, Ferrari A, Michelutti A, Simeone E, Astolfi A, Abbenante MC, Parisi S, Cattina F, Malagola M, Russo D, Damiani D, Gherlinzoni F, Gottardi M, Baccarani M, Fanin R, Martinelli G. Iacobucci I, et al. Among authors: malagola m. Pharmacogenomics J. 2013 Aug;13(4):335-41. doi: 10.1038/tpj.2012.13. Epub 2012 May 15. Pharmacogenomics J. 2013. PMID: 22584460
Profile of toll-like receptors on peripheral blood cells in relation to acute graft-versus-host disease after allogeneic stem cell transplantation.
Skert C, Fogli M, Perucca S, Garrafa E, Fiorentini S, Filì C, Bergonzi C, Malagola M, Turra A, Colombi C, Cattina F, Alghisi E, Caruso A, Russo D. Skert C, et al. Among authors: malagola m. Biol Blood Marrow Transplant. 2013 Feb;19(2):227-34. doi: 10.1016/j.bbmt.2012.09.013. Epub 2012 Sep 26. Biol Blood Marrow Transplant. 2013. PMID: 23022388 Free article.
Myeloid Sarcoma: The Clinician's Point of View.
Malagola M, Tiribelli M, Russo D, Candoni A, Visani G, Isidori A. Malagola M, et al. Leuk Res Treatment. 2011;2011:410291. doi: 10.4061/2011/410291. Epub 2011 Apr 27. Leuk Res Treatment. 2011. PMID: 23213542 Free PMC article.
Prospective phase II Study on 5-days azacitidine for treatment of symptomatic and/or erythropoietin unresponsive patients with low/INT-1-risk myelodysplastic syndromes.
Filì C, Malagola M, Follo MY, Finelli C, Iacobucci I, Martinelli G, Cattina F, Clissa C, Candoni A, Fanin R, Gobbi M, Bocchia M, Defina M, Spedini P, Skert C, Manzoli L, Cocco L, Russo D. Filì C, et al. Among authors: malagola m. Clin Cancer Res. 2013 Jun 15;19(12):3297-308. doi: 10.1158/1078-0432.CCR-12-3540. Epub 2013 Apr 17. Clin Cancer Res. 2013. PMID: 23596104 Clinical Trial.
Effects and outcome of a policy of intermittent imatinib treatment in elderly patients with chronic myeloid leukemia.
Russo D, Martinelli G, Malagola M, Skert C, Soverini S, Iacobucci I, De Vivo A, Testoni N, Castagnetti F, Gugliotta G, Turri D, Bergamaschi M, Pregno P, Pungolino E, Stagno F, Breccia M, Martino B, Intermesoli T, Fava C, Abruzzese E, Tiribelli M, Bigazzi C, Cesana BM, Rosti G, Baccarani M. Russo D, et al. Among authors: malagola m. Blood. 2013 Jun 27;121(26):5138-44. doi: 10.1182/blood-2013-01-480194. Epub 2013 May 15. Blood. 2013. PMID: 23678005 Free article. Clinical Trial.
Long term outcome of Ph+ CML patients achieving complete cytogenetic remission with interferon based therapy moving from interferon to imatinib era.
Malagola M, Breccia M, Skert C, Cancelli V, Soverini S, Iacobucci I, Cattina F, Liberati AM, Tiribelli M, Annunziata M, Trabacchi E, De Vivo A, Castagnetti F, Martinelli G, Fogli M, Stagno F, Pica G, Iurlo A, Pregno P, Abruzzese E, Pardini S, Bocchia M, Russo S, Pierri I, Lunghi M, Barulli S, Merante S, Mandelli F, Alimena G, Rosti G, Baccarani M, Russo D. Malagola M, et al. Am J Hematol. 2014 Feb;89(2):119-24. doi: 10.1002/ajh.23593. Am J Hematol. 2014. PMID: 24122886 Free article.
146 results